Development of a Neurotensin-Derived 68 Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS 1 Receptor-Expressing Tumors.

MLA

Schindler, Lisa, et al. “Development of a Neurotensin-Derived 68 Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS 1 Receptor-Expressing Tumors.” Cancers, vol. 14, no. 19, Oct. 2022. EBSCOhost, https://doi.org/10.3390/cancers14194922.

APA

Schindler, L., Moosbauer, J., Schmidt, D., Spruss, T., Grätz, L., Lüdeke, S., Hofheinz, F., Meister, S., Echtenacher, B., Bernhardt, G., Pietzsch, J., Hellwig, D., & Keller, M. (2022). Development of a Neurotensin-Derived 68 Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS 1 Receptor-Expressing Tumors. Cancers, 14(19). https://doi.org/10.3390/cancers14194922

Chicago

Schindler, Lisa, Jutta Moosbauer, Daniel Schmidt, Thilo Spruss, Lukas Grätz, Steffen Lüdeke, Frank Hofheinz, et al. 2022. “Development of a Neurotensin-Derived 68 Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS 1 Receptor-Expressing Tumors.” Cancers 14 (19). doi:10.3390/cancers14194922.